Sotera Health (SHC) Stock Forecast & Price Target

Sotera Health Company is projected to achieve an adjusted EBITDA growth rate of 6.7% annually from $589 million in 2025 to $716 million in 2028, with margin expansions expected to reach 51.7%. Management has reaffirmed revenue growth guidance of 4.5-6%, while also indicating an adjusted EBITDA margin improvement of approximately 90 basis points driven by enhanced performance in its Sterigenics segment. Furthermore, a strategic shift towards higher-margin lab testing services within Nelson Labs is anticipated to contribute significantly to nearly 100 basis points of adjusted EBITDA margin expansion in the current year, indicating a robust financial trajectory for the company.

Sotera Health has experienced a decline in adjusted EBITDA margins, dropping approximately 180 basis points from 51.7% in 2021 to 49.9% in 2024, primarily due to inflation, overstaffing, and unfavorable conditions in its Nelson Labs business. The company’s revenue growth has been adversely impacted by the loss of higher-margin COVID-related testing volumes, leading to expectations of a mid-single-digit decline in sales for the Nelson Labs segment in 2025, exacerbated by a shift towards lower-margin services and customer supply chain challenges. Additionally, despite previously strong organic revenue growth averaging nearly 9.0% from 2021 to 2022, the stock has significantly underperformed the S&P 500 since its IPO, reflecting ongoing financial pressures and a challenging market environment.